Table 4 Comparison of CAEBV with and without CAD

Course of disease (d)

70.57

86.31

Lymphadenopathy

5

13

Hepatomegaly

10

13

Splenomegaly

8

15

WBC (× 10⁹/L)

5.03 (1.49–9.91)

4.82 (1.13–12.98)

ANC (× 10⁹/L)

2.66 (0.42–5.11)

1.74 (0.36–7.89)

Hb (g/L)

106.00 (73.00–131.00)

105.00 (21.00–341.00)

PLT (× 10⁹/L)

137.00 (30.00–422.00)

187.00 (21.00–341.00)

ALT (U/L)

230. 70 (22.80–1928.00)

109.85 (19.30–695.00)

AST (U/L)

124.80 (12.20–1806.00)

46.50 (9.90–662.90)

TG (mmol/L)

2.91 (1.20–5.24)

1.71 (0.66–5.71)

Fib (g/L)

2.12 (1.35–3.11)

1.29 (0.90–3.50)

CK-MB (U/L)

21.00 (10.00–33.00)

17.50 (6.00–45.00)

LDH (U/L)

433.500 (226.00–9934.00)

219.50 (201.00–1393.00)

CD4 + /CD8 + 

0.75 (0.02–2.03)

2.31 (0.73–7.95)

SF (ug/L)

162.3 (27.80–91,893.20)

156.05 (24.70–17,043.00)

sCD25 (ng/L)

3848.40 (1504.00–23,684.00)

9282.20 (1500.00–40,623.00)

EBV (plasma) (Copies/mL)

1.81 (0.15–176.00) × 10⁴

2.65 (0.15–755.00) × 10⁴

EBV (whole blood) (Copies/mL)

1.18 (0.02–3.96) × 10⁷

0.17 (0.016–3.97) × 10⁷

NK cell activity (%)

15.30 (12.84–20.52)

14.52 (10.82–50.80)

IFN-γ (ng/L)

13.68 (3.41–790.41)

76.29 (0.00–769.91)

TNF-α (ng/L)

2.66 (0.00–525.62)

2.37 (0.00–244.33)

IL-6 (ng/L)

14.24 (4.98–2500.00)

31.64 (0.00–2500.00)

IL-10 (ng/L)

5.14 (1.79–270.01)

6.14 (1.93–75.72)